PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.89%
Cash & equivalents declining -7.89% while TRVN's grows 6.82%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-7.89%
Cash + STI yoy 0.5-0.75x TRVN's -11.60%. Martin Whitman would worry about lagging short-term reserves. Confirm debt coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.62%
0.5-0.75x TRVN's -11.04%. Martin Whitman might see risk if this hampers near-term financial flexibility.
-4.83%
≥ 1.5x TRVN's -1.96%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.38%
≥ 1.5x TRVN's -1.75%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-7.59%
0.5-0.75x TRVN's -10.98%. Martin Whitman worries about slower asset growth than competitor. Is it strategy or constraint?
-25.56%
Less than half of TRVN's 23.74%. David Dodd sees a more disciplined AP approach or lower volume.
-49.71%
Higher Short-Term Debt Growth compared to TRVN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
240.62%
Below half of TRVN's -100.00%. Michael Burry suspects a big gap in pre-sales traction.
-18.75%
Less than half of TRVN's 4.54%. David Dodd sees fewer expansions in other current obligations.
-24.27%
Above 1.5x TRVN's -8.17%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.27%
Above 1.5x TRVN's -2.43%. Michael Burry sees a potential leverage warning sign.
5.27%
Above 1.5x TRVN's 0.01%. Michael Burry suspects heavy new equity expansion or dilution.
-5.68%
0.5-0.75x TRVN's -9.59%. Martin Whitman is wary of weaker retention or lower profitability.
-17.53%
Less than half of TRVN's 149.24%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-4.86%
Below half TRVN's -12.73%. Michael Burry sees potential underperformance in building shareholder capital.
-7.59%
0.5-0.75x TRVN's -10.98%. Martin Whitman sees underexpansion or possible missed opportunities.
No Data
No Data available this quarter, please select a different quarter.
-49.71%
Less than half of TRVN's 0.16%. David Dodd sees less overall debt expansion vs. competitor.
7.55%
Less than half of TRVN's -14.31%. David Dodd sees better deleveraging or stronger cash buildup than competitor.